Wechselwirkungen · Abrysvo
Abrysvo powder and solvent for solution for injection Abrysvo powder and solvent for solution for injection in multidose container Respiratory syncytial virus vaccine (bivalent, recombinant) · Abschnitt 4.5 · PDF-Seite 4
HOS-150893 · Präparat HOS-100410
A minimum interval of two weeks is recommended between administration of Abrysvo and administration of a tetanus, diphtheria and acellular pertussis vaccine (Tdap). There were no safety concerns when Abrysvo was co-administered with Tdap in healthy non-pregnant women. Immune responses to RSV A, RSV B, diphtheria and tetanus on co-administration were non-inferior to those after separate administration. However, the immune responses to the pertussis components were lower on co-administration compared to separate administration and did not meet the criteria for non- inferiority. The clinical relevance of this finding is unknown.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pertussis vaccine (HOS-115105)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-14T08:35:00Z · SHA-256 f35f8d66cc17ad69b294df5fef1659ab055ce8cc61b4d8d43ed5c5696af3273a · Passage 1890e69a2a79053a5e519e404f1b567b5929d3100dc774938a637c9e3349774c · Zeichen 264–897 im Abschnitt